Effect of GLP-1 on Postprandial Lipid Metabolism

NCT ID: NCT01760772

Last Updated: 2013-01-04

Basic Information

• Recruitment Status: UNKNOWN
• Clinical Phase: NA
• Total Enrollment: 42 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2013-02-28
• Study Completion Date: 2015-02-28

Brief Summary

Individuals with obesity have an increased risk for heart disease and diabetes. There are current drugs on the market that target the hormone, Glucagon like peptide-1 (GLP-1) to treat diabetes. The investigators want to determine if targeting this hormone will also help people with high cholesterol and triglycerides. In this study, the investigators are looking at the role of GLP-1 in healthy subjects and subjects that have had bariatric surgery.

Detailed Description

Major consequences of the global pandemic of obesity include cardiovascular disease, type 2 diabetes and dyslipidemia. The dyslipidemia of obesity commonly consists of fasting hypertriglyceridemia with increased plasma very low-density lipoprotein (VLDL), reduced high-density lipoprotein (HDL) and the presence of small, dense low-density lipoprotein (LDL). However, more recently, increased secretion of intestinally derived lipoproteins (LPs) has been recognized as contributing to this dyslipidemic profile and postprandial lipemia has been linked to adverse health outcomes. Glucagon-like peptide-1 (GLP-1), a hormone secreted during meal absorption that plays a key role in the control of plasma glucose has been implicated as a candidate hormone for regulating intestinal lipid metabolism. Studies in rodents demonstrate that treatment with the GLP-1R agonist; exendin-4 (Ex-4) reduced postprandial chylomicron (CM) production and CM-associated cholesterol and triglyceride (TG). Similar results were found in Type 2 diabetes (T2D) subjects treated with Ex-4; in these reports there was a reduction in both intestinally derived LP production and total plasma TG. The objective of this study is to determine whether GLP-1 is involved in the physiologic regulation of postprandial lipid metabolism in healthy women, and to test the hypothesis that the improved lipid parameters found in overweight women who have had bariatric surgery are mediated by GLP-1. The specific aims for this project will 1) determine if either pharmacologic treatment with GLP-1 and/or antagonism of endogenous GLP-1 activity improves postprandial lipid metabolism in healthy subjects and 2) determine the role of elevated postprandial GLP-1 levels on lipid metabolism in obese subjects who have had a sleeve gastrectomy. The investigators will use infusions of synthetic GLP-1 with the native hormone to confirm the lipid-lowering results that have been published using pharmacologic GLP-1 receptor (GLP-1R) agonists. The investigators will also use the GLP-1R antagonist exendin-(9-39) to determine the role of endogenous GLP-1 on lipemia after a test meal. A demonstration that this is a physiologic action would expand the current understanding of lipid metabolism, provide new insight into the effects of bariatric surgery, and allow the design of more refined, mechanistic studies of this process. In addition, the potential for GLP-1R signaling to promote lipid metabolism has direct translational importance in that therapies already exist that could capitalize on this mechanism. Understanding the role of GLP-1R regulation of lipid absorption and clearance could lead to more appropriate targeting of GLP-1 based drugs to specific diabetic patients, i.e. ones with problematic dyslipidemia and higher risk for cardiovascular disease. Moreover, understanding the effects of GLP-1 on plasma lipids could eventually lead to new approaches for treating nondiabetic dyslipidemic persons.

Conditions

Heart Disease

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: FACTORIAL
• Primary Study Purpose: BASIC_SCIENCE
• Blinding Strategy: SINGLE

Study Groups

Saline

0.9% saline

Group Type: PLACEBO_COMPARATOR

saline

Intervention Type: OTHER

Constant infusion

Exendin-9 (Ex-9)

Bolus of Ex-9 (7,500 pmol/kg) followed by a continuous infusion at 750 pmol/kg/min

Group Type: EXPERIMENTAL

Exendin-9

Intervention Type: DRUG

Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min

GLP-1

GLP-1 infusion at 0.3 pmol/kg/min

Group Type: EXPERIMENTAL

GLP-1

Intervention Type: DRUG

Constant infusion of GLP-1 at 0.3 pmol/kg/min

Interventions

Exendin-9

Bolus of Ex-9 (7500 pmol/kg) over 1 minute followed by continuous infusion at 750 pmol/kg/min

Intervention Type: DRUG

GLP-1

Constant infusion of GLP-1 at 0.3 pmol/kg/min

Intervention Type: DRUG

saline

Constant infusion

Intervention Type: OTHER

Other Intervention Names

Synthetic exendin (9-39) injection; 7-36 amide

Eligibility Criteria

Inclusion Criteria

• Aim 1: Healthy, normolipemic men and postmenopausal women; aged 40-60 years; BMI between 25-35
• Aim 2: Men and postmenopausal women after successful vertical sleeve gastrectomy (VSG) surgery and age- and weight-matched non-surgical control men and postmenopausal women; ages between 40-6- years; BMI between 28-35; steady weight for at least 3 months prior to study

Exclusion Criteria

• History or clinical evidence of impaired fasting glucose or diabetes mellitus, myocardial infarction or symptoms of congestive heart failure, history or active liver or renal disease, calculated glomerular filtration rate < 60 mL/min).
• History of extreme dyslipidemia (i.e. familial hypercholesterolemia) or Cardiovascular disease (CVD).
• Fasting plasma total cholesterol > 200 mg/dL and fasting plasma TGs > 150 mg/dL.
• Surgery within 6 months.
• Pregnancy or lactation.
• Anemia defined as hematocrit < 33%.
• History of cancer or anorexia nervosa or GI disorders.
• Use of medications that alter insulin sensitivity (i.e. niacin, glucocorticoids, metformin) or lipid metabolism (i.e. statin, niacin, fibrate, ezetimibe).
• Plasma HbA1c > 6.0.
• Fasting glucose > 110 mg/dL
• Electrocardiogram (ECG) abnormalities: evidence of ischemia or arrhythmia.

• History of CVD.
• Fasting plasma total cholesterol > 250 mg/dL and fasting plasma TGs > 300 mg/dL.
• Surgical intervention within 6 months.
• Anemia defined as hematocrit < 33%.
• History of cancer or anorexia nervosa or other major GI disease or surgery.
• Use of medications that alter insulin sensitivity (i.e. niacin, glucocorticoids, metformin) or lipid metabolism (i.e. statin, ezetimibe).
• HbA1c > 6.0.
• Fasting glucose > 110 mg/dL
• Electrocardiogram (ECG) abnormalities: evidence of ischemia or arrhythmia.
• Significant renal, hepatic or pulmonary disease.

• Minimum Eligible Age: 40 Years
• Maximum Eligible Age: 60 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

David Dalessio

OTHER

Sponsor Role: lead

Responsible Party

David Dalessio

Professor

Responsibility Role: SPONSOR_INVESTIGATOR

Principal Investigators

Michelle R Adams, PhD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinnati

David D'Alessio, MD

Role: PRINCIPAL_INVESTIGATOR

University of Cincinnati

Locations

Veteran's Affairs Clinical Research Unit

Cincinnati, Ohio, United States

Countries

United States

Central Contacts

Michelle R Adams, PhD

Role: CONTACT

michelle.adams@uc.edu

513-558-6920

David D'Alessio, MD

Role: CONTACT

DALESSD@UCMAIL.UC.EDU

513-558-6689

Facility Contacts

Michelle R Adams, PhD

Role: primary

michelle.adams@uc.edu

513-558-6920

Other Identifiers

12-09-20-01

Identifier Type: -

Identifier Source: org_study_id